問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberMK-1084-012
NCT Number(ClinicalTrials.gov Identfier)-
Active

2025-06-10 - 2033-12-31

Phase III

Recruiting4

ICD-10C19

Malignant neoplasm of rectosigmoid junction

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9154.0

Malignant neoplasm of rectosigmoid junction

-

  • Trial Applicant

    Merck Sharp & Dohme (I.A.) LLC

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/13

Investigators and Locations

Principal Investigator Hung-Chih Hsu Division of Hematology & Oncology
Linkou Chang Gung Medical Foundation

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Hao-Wei Teng Division of Hematology & Oncology
Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yu-Min Yeh Division of Hematology & Oncology
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Kun-Huei Yeh
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    15 participants

  • Global

    477 participants

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB